Crinetics Pharmaceuticals Shares Surged This Week

Shares of Crinetics Pharmaceuticals (Nasdaq: CRNX) jumped as much as 98.7% this week, currently trading around $83.48 after Vertex Pharmaceuticals (Nasdaq: VRTX) announced a definitive agreement to acquire the San Diego-based biopharmaceutical company for $85.00 per share in cash.

The all-cash transaction, unveiled late Monday, values Crinetics at approximately $10 billion in equity, or roughly $8.8 billion net of the company’s cash reserves — a 102% premium to its prior closing price.

Vertex’s Biggest Deal in Years

The deal marks Vertex’s largest acquisition in years and a strategic pivot into endocrinology, an area outside its traditional cystic fibrosis and pain-management focus. Crinetics brings two marquee assets: PALSONIFY (paltusotine), the first and only once-daily oral therapy approved for acromegaly, recently cleared by both the FDA and European Commission; and atumelnant, a late-stage oral candidate for congenital adrenal hyperplasia with additional potential in Cushing’s syndrome. Together, Vertex projects the drugs could generate more than $5 billion in combined peak annual sales.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Financing and Timeline

Vertex plans to fund the acquisition using existing cash and $4.5 billion in committed bridge financing from Bank of America and Morgan Stanley. Both companies’ boards approved the deal unanimously, with closing expected in the third quarter of 2026.

Sector Reaction and Legal Scrutiny

The rally comes just days after UBS initiated coverage of Crinetics with a Buy rating and $55 price target, citing the stock’s steep pullback since January as an attractive entry point — a call quickly overtaken by the buyout news. The acquisition has also stirred renewed takeover speculation across the biotech sector, with obesity-focused peer Viking Therapeutics drawing fresh investor attention. Separately, law firm Halper Sadeh LLC announced it is investigating whether Crinetics’ board secured a fair price for shareholders.